Loading...
XNYSBDX
Market cap65bUSD
Dec 24, Last price  
226.95USD
1D
0.23%
1Q
-3.51%
Jan 2017
37.09%
Name

Becton Dickinson and Co

Chart & Performance

D1W1MN
XNYS:BDX chart
P/E
38.60
P/S
3.26
EPS
5.88
Div Yield, %
1.67%
Shrs. gr., 5y
1.15%
Rev. gr., 5y
3.14%
Revenues
20.18b
+4.16%
5,414,681,0005,834,827,0006,359,708,0007,155,910,0007,160,874,0007,372,333,0007,828,904,0007,708,382,0008,054,000,0008,446,000,00010,282,000,00012,483,000,00012,093,000,00015,983,000,00017,290,000,00017,117,000,00020,248,000,00018,870,000,00019,372,000,00020,178,000,000
Net income
1.71b
+14.89%
722,263,000752,280,000890,033,0001,126,996,0001,231,603,0001,317,610,0001,270,994,0001,169,927,0001,293,000,0001,185,000,000695,000,000976,000,0001,100,000,000311,000,0001,220,000,000874,000,0002,092,000,0001,779,000,0001,484,000,0001,705,000,000
CFO
3.84b
+28.60%
1,226,174,0001,076,400,0001,240,436,0001,687,099,0001,716,816,0001,744,268,0001,716,000,0001,760,228,0001,507,000,0001,744,000,0001,729,000,0002,559,000,0002,550,000,0002,865,000,0003,330,000,0003,539,000,0004,647,000,0002,633,000,0002,989,000,0003,844,000,000
Dividend
Sep 09, 20240.95 USD/sh
Earnings
Jan 30, 2025

Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
URL
https://www.bd.com/
IPO date
Sep 25, 1963
Employees
77,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
20,178,000
4.16%
19,372,000
2.66%
18,870,000
-6.81%
Cost of revenue
12,243,000
12,439,000
11,649,000
Unusual Expense (Income)
NOPBT
7,935,000
6,933,000
7,221,000
NOPBT Margin
39.33%
35.79%
38.27%
Operating Taxes
300,000
132,000
148,000
Tax Rate
3.78%
1.90%
2.05%
NOPAT
7,635,000
6,801,000
7,073,000
Net income
1,705,000
14.89%
1,484,000
-16.58%
1,779,000
-14.96%
Dividends
(1,100,000)
(1,114,000)
(1,082,000)
Dividend yield
1.57%
1.49%
1.69%
Proceeds from repurchase of equity
(500,000)
(500,000)
BB yield
0.71%
0.78%
Debt
Debt current
2,170,000
1,141,000
2,179,000
Long-term debt
17,940,000
16,175,000
14,763,000
Deferred revenue
Other long-term liabilities
4,501,000
5,191,000
877,000
Net debt
17,809,000
15,892,000
15,928,000
Cash flow
Cash from operating activities
3,844,000
2,989,000
2,633,000
CAPEX
(725,000)
(874,000)
(973,000)
Cash from investing activities
(5,514,000)
(716,000)
(3,231,000)
Cash from financing activities
2,087,000
(1,957,000)
(591,000)
FCF
8,230,000
5,343,000
6,267,000
Balance
Cash
2,301,000
1,424,000
1,014,000
Long term investments
Excess cash
1,292,100
455,400
70,500
Stockholders' equity
16,510,000
14,381,000
14,036,000
Invested Capital
49,207,900
46,824,600
42,015,500
ROIC
15.90%
15.31%
16.77%
ROCE
15.71%
14.66%
15.32%
EV
Common stock shares outstanding
291,009
288,392
287,364
Price
241.10
-6.74%
258.53
16.02%
222.83
-9.35%
Market cap
70,162,270
-5.90%
74,557,984
16.44%
64,033,320
-10.82%
EV
87,971,270
90,449,984
79,963,320
EBITDA
10,221,000
9,221,000
9,450,000
EV/EBITDA
8.61
9.81
8.46
Interest
528,000
452,000
398,000
Interest/NOPBT
6.65%
6.52%
5.51%